Batu Biologics Completes Seed Round Financing

Batu Biologics Continues Fight in War Against Lung Cancer

Closure of $1 million seed round to support development of anti-angiogenic immune therapy, ValloVax™

Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer in the United States. Batu leveraged primarily private and angel funding to attain this fundraising goal.

Read the full article at businesswire.com

Continue →
0

ValloVax Efficacy Augmented by Checkpoint Inhibitors

Batu Biologics Reports Combination Therapy Boosts Results in Tumor Blood Vessel-Killing Strategy

Company Files Patent on Second Generation Cancer Therapy

Batu Biologics, an immuno-oncology company dedicated to the commercialization of its first-in-class tumor blood vessel targeting vaccine, ValloVax, reported today filing of a patent application covering a unique combination therapy of its vaccine together with two classes of “checkpoint inhibitors.”

Read the full article at businesswire.com

Continue →
0

Batu Biologics files IP for immune modulator

Batu Biologics Files Patent on Blood Derived Anti-Cancer Immunomodulator

Cancer Angiogenesis Vaccine Company Expands its Therapeutic Pipeline

Batu Biologics announced today filing of a patent application covering a recent finding by the company regarding ability to stimulate innate immune system through products that are coaxed out of white blood cells by stimulation with non-toxic agents.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Appoints Dr. Santosh Kesari to SAB

Batu Biologics Appoints Dr. Santosh Kesari to Scientific Advisory Board

UC San Diego Moores Cancer Expert to evaluate the clinical potential of ValloVax for Glioblastoma

Batu Biologics, an immuno-oncology company based out of San Diego dedicated to the development of its polyvalent tumor endothelium vaccine, ValloVax, announced today the appointment of Santosh Kesari, MD, PhD, FANA to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Appoints Alan Lewis to Chairman of the Board

Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis as Chairman of the Board

World Class Industry Expert to Accelerate Development of Cancer Immunotherapeutic Platform after IND Filing for Lung Cancer Indication

Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors.

Read the full article at businesswire.com

Continue →
0

Startup applies to test cancer therapy

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.

The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the U.S. Food and Drug Administration approves the application.

ValloVax™ targets proteins found in blood vessels induced by cancer that are not present in ordinary ...

Continue →
0
Page 2 of 5 12345